Tonix Pharmaceuticals Targets Stress Disorder, Lyme Disease, and Rare Conditions With Advancing Pipeline
SHERIDAN, WYOMING – April 14, 2026 – Clinical-stage biopharmaceutical company Tonix Pharmaceuticals is advancing a pipeline of investigational treatments across four disease areas — central nervous system disorders, immunology, infectious disease, and rare disease — with several programs in active clinical development and key data readouts expected before the end of 2026. The company focuses on conditions that are often chronic, complex, and poorly served by existing therapies, including acute stress disorder, migraine, organ transplant rejection, and Prader-Willi syndrome. None of Tonix's candidates have been approved for any indication, but multiple programs have moved through Phase 1 and into Phase 2 stages. For patients living with conditions that have few or no approved treatments, the company's activity represents a meaningful expansion of the clinical options being explored.